INFINITY PHARMACEUTICALS INC (INFI)

US45665G3039 - Common Stock

0.0447  -0.04 (-46.98%)

After market: 0.04 0 (-10.51%)

INFINITY PHARMACEUTICALS INC

NASDAQ:INFI (9/13/2023, 7:17:37 PM)

After market: 0.04 0 (-10.51%)

0.0447

-0.04 (-46.98%)

Chartmill TA Rating
Chartmill Setup Rating
Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
Chartmill FA Rating
Valuation
Growth
Profitability
Health
Dividend
Overview
Earnings (Last)08-08 2023-08-08/amc
Earnings (Next)11-13 2023-11-13/amc
Ins Owners1.29%
Inst Owners23.53%
Market Cap4.06M
Shares90.76M
PEN/A
Fwd PEN/A
Dividend YieldN/A
Analysts43.33
IPO07-27 2000-07-27
Stock Screener Links
Screen Image

Nasdaq Stock Screener

Find more stocks on Nasdaq

Screen Image

USA Stock Screener

Find more stocks on the USA

Screen Image

GICS Sector Stock Screener

Find competitors from the same sector on the USA

Screen Image

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Screen Image

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Screen Image

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Screen Image

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

INFI Daily chart

Company Profile

Infinity Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the business of developing novel medicines for people with cancer. The company is headquartered in Cambridge, Massachusetts and currently employs 30 full-time employees. The company went IPO on 2000-07-27. The firm is focused on advancing eganelisib, also known as IPI-549, an orally administered, clinical-stage, immuno-oncology product candidate that reprograms macrophages through selective inhibition of the enzyme phosphoinositide-3-kinase-gamma (PI3K-gamma). Its eganelisib clinical development program includes MAcrophage Reprogramming in Immuno-Oncology-3 (MARIO-3), MARIO-275 and MARIO-1. MARIO-3 is a multi-arm Phase II study designed to evaluate eganelisib in the front-line treatment for both metastatic triple-negative breast cancer (TNBC), and renal cell carcinoma (RCC). MARIO-275 is its global, randomized, placebo-controlled Phase II study evaluating the effect of adding eganelisib to nivolumab, also known as Opdivo, in checkpoint-naive advanced urothelial cancer (UC). MARIO-1 is in the Phase I/Ib clinical study.

Company Info

INFINITY PHARMACEUTICALS INC

1100 Massachusetts Avenue, Floor 4

Cambridge MASSACHUSETTS 02138

P: 16174531000.0

CEO: Adelene Q. Perkins

Employees: 30

Website: https://www.infi.com/

INFI News

News Image7 hours ago - TheNewswire.comROSEN, LEADING INVESTOR COUNSEL, Encourages Infinity Pharmaceuticals, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - INFI

WHY: NEW YORK, NY - (NewMediaWire) - September 24, 2023 - Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) between January 5, 2022 and July 24, 2023, both dates inclusive (the “Class Period”), of the important October 16, 2023 lead plaintiff deadline.

News Image13 hours ago - NewMediaWireROSEN, LEADING INVESTOR COUNSEL, Encourages Infinity Pharmaceuticals, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - INFI

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

News Image2 days ago - Faruqi & Faruqi, LLPINFINITY INVESTOR DEADLINE APPROACHING: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Infinity To Contact Him Directly To Discuss Their Options

/PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Infinity Pharmaceuticals, Inc....

News Image2 days ago - Bragar Eagel & SquireBragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Infinity, Shift4, and Comerica and Encourages Investors to Contact the Firm
News Image3 days ago - TheNewswire.comROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Infinity Pharmaceuticals, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - INFI

WHY: NEW YORK, NY - (NewMediaWire) - September 21, 2023 - Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) between January 5, 2022 and July 24, 2023, both dates inclusive (the “Class Period”), of the important October 16, 2023 lead plaintiff deadline.

News Image3 days ago - Pomerantz LLPSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Infinity Pharmaceuticals, Inc. - INFI

/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Infinity Pharmaceuticals, Inc. ("Infinity" or the "Company") (NASDAQ: INFI)....

INFI Twits

Here you can normally see the latest stock twits on INFI, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.

Example Twits:

Twits example